S-3799-119
Placed on Senate Legislative Calendar under General Orders. Calendar No. 442.
Sponsored by Roger Marshall (R-KS)
What it does
This bill would reauthorize the Healthy Start Initiative — a federal grant program targeting infant mortality and maternal health disparities — by authorizing $145,250,000 per year for fiscal years 2027 through 2031. It amends the Public Health Service Act to extend the program's funding authorization for five years. The committee amendment adjusted the originally proposed $145,000,000 annual figure slightly upward and shifted the funding window by one year.
Who benefits
Pregnant women and new mothers in high-risk communities, particularly those in areas with elevated infant mortality rates. Infants in underserved communities who receive health screenings and follow-up care. Community health organizations and local nonprofits that receive Healthy Start grants and employ outreach workers. Public health researchers who study maternal and infant health outcomes. Hospitals and clinics in low-income areas that partner with Healthy Start grantees.
Who is hurt
Federal taxpayers who bear the cost of the $145.25 million annual appropriation. Competing federal health programs that may face indirect budget pressure in discretionary spending negotiations. Organizations that applied for Healthy Start grants but were not selected, as the program's fixed funding cap limits the number of grantees that can be supported.
Supporters argue
Supporters argue that the United States has one of the highest infant mortality rates among high-income nations, and that racial and geographic disparities in maternal and infant outcomes remain severe — with Black infants dying at more than twice the rate of white infants, according to CDC data. They contend that Healthy Start has operated since 1991 with documented success in reducing infant mortality in targeted communities, and that a five-year reauthorization provides the program stability needed for grantees to plan and sustain community health workforces.
Opponents argue
Opponents argue that reauthorizing a decades-old program without requiring a rigorous independent evaluation of its effectiveness fails to ensure federal dollars are producing measurable improvements in infant mortality or maternal health outcomes. They contend that the modest funding increase — roughly $250,000 above the prior authorization level — does not keep pace with inflation, effectively reducing the program's real purchasing power, and that Congress should instead conduct a comprehensive review of whether Healthy Start's grant structure is the most cost-effective mechanism for addressing maternal and infant health disparities.